MX2014000130A - Procedimientos y composiciones para la inhibicion de resorcion osea. - Google Patents
Procedimientos y composiciones para la inhibicion de resorcion osea.Info
- Publication number
- MX2014000130A MX2014000130A MX2014000130A MX2014000130A MX2014000130A MX 2014000130 A MX2014000130 A MX 2014000130A MX 2014000130 A MX2014000130 A MX 2014000130A MX 2014000130 A MX2014000130 A MX 2014000130A MX 2014000130 A MX2014000130 A MX 2014000130A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- inhibition
- compounds
- disclosed
- btk
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
En el presente documento se desvelan procedimientos y compuestos para inhibir resorción ósea y/o de cartílago en un individuo. Los procedimientos comprenden administrar al individuo una composición que comprende una cantidad terapéuticamente eficaz de un compuesto que es un inhibidor irreversible de una tirosina cinasa de Bruton (BTK), o una sal farmacéuticamente aceptable de la misma. También se describen inhibidores irreversibles de Btk y procedimientos para la preparación de los compuestos. También se desvelan composiciones farmacéuticas que incluyen los compuestos. Procedimientos de uso de los inhibidores de Btk se desvelan, solos o en combinación con otros agentes terapéuticos, para la inhibición de metástasis de cáncer, y para inhibición de la resorción ósea o de cartílago en pacientes con cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161502271P | 2011-06-28 | 2011-06-28 | |
PCT/US2012/044708 WO2013003629A2 (en) | 2011-06-28 | 2012-06-28 | Methods and compositions for inhibition of bone resorption |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2014000130A true MX2014000130A (es) | 2014-05-01 |
Family
ID=47424803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014000130A MX2014000130A (es) | 2011-06-28 | 2012-06-28 | Procedimientos y composiciones para la inhibicion de resorcion osea. |
Country Status (7)
Country | Link |
---|---|
US (1) | US20130178483A1 (es) |
EP (1) | EP2726077A4 (es) |
AU (1) | AU2012275275A1 (es) |
BR (1) | BR112013033534A2 (es) |
CA (1) | CA2840413A1 (es) |
MX (1) | MX2014000130A (es) |
WO (1) | WO2013003629A2 (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8491927B2 (en) * | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
EP2710005B1 (en) | 2011-05-17 | 2016-10-05 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
US9376438B2 (en) | 2011-05-17 | 2016-06-28 | Principia Biopharma, Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
CA2841111A1 (en) | 2011-07-08 | 2013-01-17 | Novartis Ag | Novel pyrrolo pyrimidine derivatives |
KR20140048968A (ko) | 2011-07-13 | 2014-04-24 | 파마시클릭스, 인코포레이티드 | 브루톤형 티로신 키나제의 억제제 |
EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
DK3689878T3 (da) | 2011-07-19 | 2021-11-08 | Merck Sharp & Dohme | 4-imidazopyridazin-1-yl-benzamider og 4-imidazotriazin-1-yl-benzamider som btk-inhibitorer |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
US20150140085A1 (en) * | 2012-06-29 | 2015-05-21 | Principia Biopharma Inc. | Formulations comprising ibrutinib |
ME03455B (me) | 2012-09-10 | 2020-01-20 | Principia Biopharma Inc | Jedinjenja pirazolopirimidina kao inhibitori kinaze |
US20140273248A1 (en) * | 2013-03-14 | 2014-09-18 | Arizona Board Of Regents On Behalf Of Arizona State University | Application of Ca Isotope Analysis to the Early Detection of Metastatic Cancer |
US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
WO2014187319A1 (en) | 2013-05-21 | 2014-11-27 | Jiangsu Medolution Ltd | Substituted pyrazolopyrimidines as kinases inhibitors |
JP6800750B2 (ja) * | 2013-08-02 | 2020-12-16 | ファーマサイクリックス エルエルシー | 固形腫瘍の処置方法 |
BR112016006978A2 (pt) | 2013-09-30 | 2017-08-01 | Pharmacyclics Llc | inibidores de tirosina quinase de bruton |
EP3060218A4 (en) | 2013-10-25 | 2017-07-19 | Pharmacyclics LLC | Methods of treating and preventing graft versus host disease |
US20150141438A1 (en) * | 2013-11-15 | 2015-05-21 | Pharmacyclics, Inc. | Methods for delaying or preventing the onset of type 1 diabetes |
CN103626774B (zh) * | 2013-11-20 | 2015-11-04 | 苏州明锐医药科技有限公司 | 伊鲁替尼的制备方法 |
US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
WO2015083008A1 (en) | 2013-12-05 | 2015-06-11 | Acerta Pharma B.V. | Therapeutic combination of a pi3k inhibitor and a btk inhibitor |
US10272083B2 (en) | 2014-01-21 | 2019-04-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
ES2841248T3 (es) | 2014-02-21 | 2021-07-07 | Principia Biopharma Inc | Sales y forma sólida de un inhibidor de BTK |
WO2015181633A2 (en) | 2014-04-11 | 2015-12-03 | Acerta Pharma B.V. | Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase |
TW201613644A (en) | 2014-06-17 | 2016-04-16 | Acerta Pharma Bv | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, and/or a JAK-2 inhibitor |
AU2015296215A1 (en) | 2014-08-01 | 2017-03-23 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
PL3179991T3 (pl) | 2014-08-11 | 2022-02-14 | Acerta Pharma B.V. | Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2 |
CN104478884A (zh) * | 2014-12-05 | 2015-04-01 | 广东东阳光药业有限公司 | 一种中间体的制备方法 |
BR112017013022A2 (pt) | 2014-12-18 | 2018-02-27 | Principia Biopharma Inc | métodos para tratar uma doença inflamatória e/ou autoimune aguda num mamífero que a necessite onde a terapia de corticosteróides é utilizada como terapia de primeira ou segunda linha e/ou para tratar uma doença inflamatória e/ou autoimune num mamífero que a necessite, onde a terapia de corticosteróides é utilizada como terapia de manutenção de primeira ou segunda linha e/ou para eliminar ou reduzir dose terapêutica de corticosteróides utilizado no tratamento de uma doença inflamatória e/ou autoimune num mamífero que a necessite, onde a terapia de corticosteróides é utilizada como terapia de manutenção crônica de primeira ou segunda linha e/ou de tratamento de uma doença autoimune e/ou inflamatória num mamífero que a necessite |
WO2016115869A1 (zh) * | 2015-01-21 | 2016-07-28 | 中国科学院合肥物质科学研究院 | Flt3激酶的新型抑制剂及其用途 |
CN105481862B (zh) * | 2015-01-21 | 2018-08-21 | 中国科学院合肥物质科学研究院 | Flt3激酶的新型抑制剂及其用途 |
CN104557946A (zh) * | 2015-02-04 | 2015-04-29 | 王立强 | 一种依鲁替尼的制备方法 |
CN106188062A (zh) * | 2015-05-08 | 2016-12-07 | 苏州鹏旭医药科技有限公司 | 依鲁替尼的制备方法、依鲁替尼的中间体及中间体的制备方法 |
US20180305350A1 (en) | 2015-06-24 | 2018-10-25 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
PT3954690T (pt) | 2015-07-02 | 2023-06-06 | Acerta Pharma Bv | Formas sólidas e formulações de (s)-4-(8-amino-3-(1-(but- 2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n- (piridin-2-il)benzamida |
CN106083860A (zh) * | 2016-06-23 | 2016-11-09 | 艾美科健(中国)生物医药有限公司 | 一种依鲁替尼中间体的合成与纯化工艺 |
JP7129704B2 (ja) | 2016-06-29 | 2022-09-02 | プリンシピア バイオファーマ インコーポレイテッド | 2-[3-[4-アミノ-3-(2-フルオロ-4-フェノキシ-フェニル)ピラゾロ[3,4-d]ピリミジン-1-イル]ピペリジン-1-カルボニル]-4-メチル-4-[4-(オキセタン-3-イル)ピペラジン-1-イル]ペント-2-エネニトリルの放出調節製剤 |
WO2018145280A1 (zh) * | 2017-02-09 | 2018-08-16 | 合肥合源药业有限公司 | Flt3激酶抑制剂或其盐的晶型及其制备方法 |
CN109970740A (zh) * | 2017-12-27 | 2019-07-05 | 广东众生药业股份有限公司 | 4-氨基-嘧啶并氮杂环衍生物及其制备方法和用途 |
CN113583001A (zh) * | 2021-07-13 | 2021-11-02 | 江苏君若药业有限公司 | 依鲁替尼的制备 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2530083T1 (sl) * | 2006-09-22 | 2016-09-30 | Pharmacyclics Llc | Inhibitorji Bruton tirozin kinaze |
US20100069458A1 (en) * | 2007-02-15 | 2010-03-18 | Peter Wisdom Atadja | Combination of lbh589 with other therapeutic agents for treating cancer |
ES2562215T3 (es) * | 2007-03-28 | 2016-03-03 | Pharmacyclics Llc | Inhibidores de la tirosina quinasa de Bruton |
US8299077B2 (en) * | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
WO2011017219A1 (en) * | 2009-08-03 | 2011-02-10 | The Regents Of The University Of California | Imidazoquinoxalinones and anti-tumor treatment |
US7741330B1 (en) * | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
-
2012
- 2012-06-28 WO PCT/US2012/044708 patent/WO2013003629A2/en active Application Filing
- 2012-06-28 US US13/536,799 patent/US20130178483A1/en not_active Abandoned
- 2012-06-28 AU AU2012275275A patent/AU2012275275A1/en not_active Abandoned
- 2012-06-28 BR BR112013033534A patent/BR112013033534A2/pt not_active IP Right Cessation
- 2012-06-28 MX MX2014000130A patent/MX2014000130A/es unknown
- 2012-06-28 EP EP12804912.9A patent/EP2726077A4/en not_active Withdrawn
- 2012-06-28 CA CA2840413A patent/CA2840413A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2840413A1 (en) | 2013-01-03 |
AU2012275275A1 (en) | 2014-01-23 |
WO2013003629A3 (en) | 2013-04-11 |
EP2726077A2 (en) | 2014-05-07 |
WO2013003629A2 (en) | 2013-01-03 |
EP2726077A4 (en) | 2014-12-10 |
BR112013033534A2 (pt) | 2017-02-07 |
US20130178483A1 (en) | 2013-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2014000130A (es) | Procedimientos y composiciones para la inhibicion de resorcion osea. | |
TN2009000444A1 (en) | Combination therapy with a compound acting as a plateletadp receptor inhibitor | |
PH12016502355B1 (en) | Pharmaceutical composition | |
MX341212B (es) | Inhibidor de bromodominio de benzodiazepina. | |
MX2011008634A (es) | Derivados de aminotetralina composiciones farmaceuticas que los contienen y su uso en terapia. | |
MX2016013529A (es) | Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos. | |
MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
MX2016008201A (es) | Tratamiento del cancer usando combinaciones de inhibidores de erk y raf. | |
EA202091303A3 (ru) | Композиция ингибитора jak для местного применения | |
MX2009006764A (es) | Pirimidinonas biciclicas y usos de la misma. | |
MX2013012588A (es) | Inhibidores de cinasa. | |
MX2009014235A (es) | 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso. | |
MX2014003080A (es) | Inhibidores sustituidos de n-[1-ciano-2- (fenil) etil]-2-azabiciclo[2.2.1] heptan-3-carboxamida de catepsina c. | |
MX336051B (es) | Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa. | |
MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
SG158863A1 (en) | Intravenous formulations of pde-5 inhibitors | |
PH12016502353A1 (en) | Pharmaceutical composition | |
MX2021010106A (es) | Inhibidores de la via de respuesta al estres integrada. | |
MX2009004017A (es) | Usos de los compuestos carboxi-amido triazol y sus sales. | |
NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
TW201613577A (en) | Pharmaceutical combinations | |
MX2013000694A (es) | Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb. | |
NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
MX2021009539A (es) | Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina. | |
MX339096B (es) | Compuestos inhibidores de metaloproteasa a base de feniletiniltiofeno y su uso en el tratamiento del dolor y otras enfermedades. |